| Overview |
| bs-11307R-RBITC |
| Prostaglandin I2 Receptor Antibody, RBITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Prostaglandin I2 Receptor |
| 101-200/386 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| IP; PGI receptor; PGI2 receptor; PI2R_HUMAN; PRIPR; Prostacyclin receptor; Prostaglandin I2 receptor; Prostanoid IP receptor; PTGIR. |
| Cyclooxygenases metabolize arachidonate to five primary prostanoids: PGE2, PGF2?, PGI2, TXA2 and PGD2. These lipid mediators interact with specific members of G protein-coupled prostanoid receptors, designated EP, FP, IP, TP and DP, respectively. The IP Receptor binds prostacyclin, PGI2, the main pro-stanoid synthesized by vascular tissues.Upon binding to the IP Receptor, prostacyclin activates adenylate cyclase primarily through the Gas protein. The gene encoding the human IP Receptor is located on chromosome 19. It is expressed as a glycosylated and phosphorylated protein, which is abundantly expressed in vascular tissues such as aorta, lung, atrium and ventricle, as well as in kidney, thymus, spleen and neurons. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz